Targeting the gut to treat multiple sclerosis

Area of Science:

• Neuroscience
• Immunology
• Microbiology

Background:

• The gut-brain axis (GBA) describes bidirectional communication between the gut microbiota and the central nervous system (CNS).
• Alterations in the GBA are implicated in the pathogenesis of multiple sclerosis (MS).
• MS patients often exhibit dysbiosis, altered metabolites, and increased intestinal permeability.

Purpose of the Study:

• To review the role of the GBA in MS pathogenesis.
• To examine therapeutic strategies targeting the GBA for MS.
• To discuss the impact of GBA modulation on neuroinflammation and demyelination.

Main Methods:

• Literature review of studies investigating the GBA in MS.
• Analysis of preclinical and clinical trials on GBA modulation (e.g., FMT, probiotics).
• Examination of mechanisms linking GBA to CNS inflammation and demyelination.

Main Results:

• Evidence suggests GBA perturbations contribute to MS.
• Microbiota manipulation studies show potential for reducing CNS inflammation.
• Inconsistencies exist across studies, and large-scale trials are needed.

Conclusions:

• The GBA is a potential therapeutic target for MS.
• Further research and large randomized controlled trials are necessary to validate GBA-modulating therapies for MS.